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A B S T R A C T
Purpose
Most anemic patients with non-deleted 5q lower-risk myelodysplastic syndromes (MDS) are treated
with erythropoiesis-stimulating agents (ESAs), with a response rate of approximately 50%. Second-
line treatments, including hypomethylating agents (HMAs), lenalidomide (LEN), and investigational
drugs, may be used after ESA failure in some countries, but their effect on disease progression and
overall survival (OS) is unknown. Here, we analyzed outcome after ESA failure and the effect of
second-line treatments.
Patients and Methods
We examined an international retrospective cohort of 1,698 patients with non-del(5q) lower-risk
MDS treated with ESAs.
Results
Erythroid response to ESAs was 61.5%, and median response duration was 17 months. Of 1,147
patients experiencing ESA failure, 653 experienced primary failure and 494 experienced relapse after
a response. Primary failure of ESAs was associated with a higher risk of acute myeloid leukemia
(AML) progression, which did not translate into an OS difference. Of 450 patients (39%) who re-
ceived second-line treatment, 194 received HMAs, 148 received LEN, and 108 received other
treatments (MISC), whereas 697 received RBC transfusions only. Five-year AML cumulative in-
cidence was 20.3%, 20.3%, and 11.3% for those receiving HMAs, LEN, and MISC, respectively
(P = .05). Five-year OS for patients receiving HMA, LEN, and MISC was 36.5%, 41.7%, and 51%,
respectively (P = .21). In a multivariable analysis adjusted for age, sex, revised International
Prognostic Scoring System score, and progression at ESA failure, there was no significant OS
difference among the three groups.
Conclusion
In this large, multicenter, retrospective cohort of patients with non-del(5q) lower-risk MDS treated
with ESAs, none of the most commonly used second-line treatments (HMA and LEN) significantly
improved OS. Early failure of ESAs was associated with a higher risk of AML progression.
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INTRODUCTION
Myelodysplastic syndromes (MDS) are clonal
diseases of hematopoietic cells occurring in older
patients, characterized by ineffective hemato-
poiesis and anemia in a majority of those af-
fected. Disease evolution is typified by worsening
cytopenias and acute myeloid leukemia (AML)
transformation.1
Erythropoiesis-stimulating agents (ESAs) are
often the first line of treatment for anemia in
patients with lower-risk MDS who lack the 5q
deletion [del(5q)]. Response rates range from
30% to 60%, with a median duration of response
of 20 to 24 months.2-4 Prognostic factors for
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better response to ESAs include low RBC transfusion requirement,
low serum erythropoietin (EPO) level, and lower-risk disease per
the revised International Prognostic Scoring System (IPSS-R).5
Treatment with ESAs may also be associated with improved sur-
vival compared with RBC transfusions alone.2,3 However, most
responders will experience relapse and become RBC transfusion
dependent.6,7
In a previous Groupe Francophone des Myelodysplasies
(GFM) study involving 253 patients with lower-risk MDS expe-
riencing ESA failure, we found that AML-free survival and
overall survival (OS) were poorer in patients experiencing early
ESA failure (ie, with absence of erythroid response or relapse
, 6 months) compared with patients experiencing later relapse
after a response.7 However, few patients in that cohort had received
treatment other than RBC transfusions after ESA failure. Recently,
the hypomethylating agents (HMAs) azacitidine (AZA) and dec-
itabine (DAC) and the immunomodulating agent lenalidomide
(LEN) demonstrated efficacy in treating anemia in patients with
lower-risk MDS without del(5q) and ESA resistance, with RBC
transfusion independence rates of 20% to 40%.8,9 These drugs are
now relatively widely used for this indication (albeit off label in all
countries in the case of LEN and in most countries outside the
United States in the case of AZA and DAC). No studies have
compared the effect of these drugs on disease progression and OS
versus best supportive care (mainly including RBC transfusions).
Although other drugs are being tested in patients with lower-risk
MDSwithout del(5q) after ESA failure, limited numbers of patients
have been treated, with short follow-up.
In this study, we analyzed data from the French and Belgian
(GFM), Italian (Fondazione Italiana Sindromi Mielodisplastiche
[FISM]), Spanish (Grupo Español de Sı́ndromes Mielodisplásicos
[GESMD]) cooperative groups, the German registry (Düsseldorf
and Münich), and US MDS Clinical Research Consortium cohorts
and data from two Greek centers to assess outcome after ESA
failure, evaluating in particular the potential effects of primary and
secondary failure on outcome and of second-line treatments,
compared with best supportive care, on AML progression and OS.
PATIENTS AND METHODS
Patients
For our study, patients with a low or intermediate-I IPSS score and
non-del(5q) MDS treated with ESAs between 1997 and 2014, for whom
ESA treatment failed (primary or secondary failure), without AML or
higher-risk MDS progression at the time of ESA failure were eligible.
Overall, 1,875 patients with lower-risk MDS according to IPSS were treated
with ESAs. We excluded 177 patients who experienced progression to an
intermediate-II or high IPSS score at ESA failure to avoid the bias of having
more patients at IPSS intermediate-II or high risk in the group treated with
HMAs at second-line treatment.
Of the remaining 1,698 patients included, 715 originated from the
GFM, 387 from the FISM, and 289 from the GESMD registries, 243 from
the US MDS Clinical Research Consortium, and 38 from the German and
26 from the Greek registries; 94 patients had been included in a prospective
GFM trial randomly assigning participants to LEN versus LEN combined
with EPO, and 76 patients had been included in a GFM trial randomly
assigning participants to AZA versus AZA combined with EPO; both trials
involved RBC transfusion-dependent lower-risk MDS patients refractory
to ESAs.8,9 All patients were classified (or reclassified) per WHO 2008
criteria. Patients with chronic myelomonocytic leukemia, other MDS or
myeloproliferative neoplasms, or del(5q) MDS were excluded. MDS with
myelofibrosis, MDS unclassified, and refractory cytopenia with unilineage
dysplasia were classified as MDS unclassified. Refractory anemia (RA) with
ring sideroblasts, refractory cytopenia with multilineage dysplasia and
ringed sideroblasts, and RAwith ring sideroblasts and thrombocytosis were
classified as MDS with ring sideroblasts; RA and refractory cytopenia with
multilineage dysplasia were combined in the RA without excess blasts
subtype.
IPSS-R score was reevaluated in all patients at ESA initiation and ESA
failure. All patients received EPO alfa, EPO beta, or darbepoietin for at least
8 weeks.
Definition of ESA Failure
Primary failure was defined as the absence of erythroid response
according to International Working Group 2006 criteria (HI-E) after
8 weeks of ESA treatment. For the 235 patients who received granulocyte
colony-stimulating factor after ESA primary failure, ESA response was
evaluated after an additional 8 to 12 weeks of treatment with ESAs plus
granulocyte colony-stimulating factor treatment. Secondary failures of
ESA treatment were defined as relapse after an initial HI-E.
For subsequent follow-up, patients were divided into those who
received HMAs, LEN, or other treatments or RBC transfusions only (MISC
group). Our combining of patients who received neither HMAs nor LEN
into one group (MISC) is justified under Statistical Methods. Second-,
third-, and fourth-line treatments were defined as the second, third, and
fourth lines of treatment administered after ESA failure, respectively.
Statistical Methods
Categorical data were described using percentages and compared
using Fisher’s exact test when appropriate, and continuous data were
described using medians and interquartile ranges and compared using the
Kruskal-Wallis exact test.
The primary end point was OS after ESA failure, calculated from the
date of relapse in patients experiencing secondary ESA failure or from the
primary failure assessment conducted 12 weeks after initiation of ESAs for
patients with primary resistance. The secondary end point was 5-year
cumulative incidence of AML transformation after ESA failure.
Covariates potentially influencing OS or AML cumulative incidence
were predefined and included second-line treatment (categorized as MISC,
HMAs, or LEN), age (dichotomized as # 75 v . 75 years), sex, IPSS-R
score at ESA failure, IPSS-R progression between ESA initiation and ESA
failure, and duration of ESA response (dichotomized as# 6 v. 6 months
as in the previous GFM study).7,10-12
Analysis of the impact of two different second-line treatments (HMAs
and LEN) compared with best supportive care andMISC was conducted by
considering such second-line treatments as time-dependent covariates,
because their effect could only be observed from the moment they were
introduced. One of the main study objectives was to analyze the impact of
HMAs and LEN on the outcome of patients for whom ESA treatment
failed; therefore, we considered patients having received other treatments
or RBC transfusions only as the MISC group. To assess whether patients
having received active treatments such as antithymocyte globulin (ATG;
which might affect OS)13 could have influenced the final results of our
multivariable analysis, we performed a sensitivity analysis excluding these
patients.
OS was analyzed using a Cox model including these predefined
covariates, considering second-line treatment as a time-dependent co-
variate, and AML cumulative incidence was analyzed using a Fine and Gray
model, considering death as a competing risk. Progression to higher-risk
MDS, considered a weaker variable than the well-documented AML
transformation, was not analyzed.
The significance of the included covariates was assessed using
the Wald test, proportional hazards assumptions using Schoenfeld re-
sidual analysis, and time-to-event graphical representations using the
1592 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Park et al
Kaplan-Meier method. The time-dependent impact of second-line
treatments was analyzed using the method described by Simon and
Makuch.14,15 Hazard ratios (HRs) and 95% CIs were estimated, with P
values , .05 denoting significance. Statistical analyses were performed
using STATA software (version 13.1; STATA, College Station, TX).
RESULTS
Baseline Characteristics of Patients Experiencing
Primary or Secondary Failure
Of the 1,698 included patients, 653 (34%) experienced pri-
mary ESA resistance and 1,045 (61.5%) responded to ESAs, of
whom 551 (32.5%) had continued response at the time of analysis
and 494 (29%) had relapsed after a median response duration of
17 months (range, 3 to 74 months; Appendix Fig A1, online only).
For the purpose of this study, only the 1,147 patients experiencing
primary or secondary failure after ESAs were analyzed. After
reclassification using IPSS-R criteria, 157 (14%), 644 (56%), 187
(16%), and 159 patients (14%), respectively, had very low, low,
intermediate, and not evaluable IPSS-R scores at ESA initiation (in
patients with a not evaluable score, marrow blasts were # 5%).
Baseline characteristics of the three groups (primary and
secondary failure and continued responders to ESAs) differed
significantly in parameters known to be associated with ESA re-
sponse, including serum EPO level, IPSS-R score, and serum
ferritin levels (Appendix Table A1, online only). In addition,
primary resistant patients were younger, were more often male,
had a lower hemoglobin level at ESA initiation, and were more
likely to have RA with excess blasts or MDS with ring sideroblasts.
Outcome of Patients Experiencing Primary Versus
Secondary Failure
Five-year cumulative incidence of AML transformation in
patients experiencing primary or secondary failure was 13.4%
(95%CI, 10.9% to 16.4%); it was 8.1% (95%CI, 5.1% to 12.8%) in
those experiencing secondary failure versus 16.7% (95% CI, 13.4%
to 20.8%) in those experiencing primary failure (P = .001; Ap-
pendix Fig A2, online only).
At last follow-up, 622 patients were alive and 525 had died.
With a median follow-up of 41 months, median survival from ESA
failure was 52.2 and 60.4 months for those with primary refractory
disease and those experiencing relapse, respectively (P = .12; Fig 1).
Subsequent Lines of Treatment
Of the 1,147 patients experiencing primary or secondary ESA
failure, 450 (39%) received a second-line treatment other than
RBC transfusions (Appendix Table A2, online only; Appendix Fig
A1), such as HMAs (n = 194 [17%], including 11 combined with
EPO) or LEN (n = 148 [13%], alone in 85 patients and combined
with EPO in 63 patients, with 31 patients having received LEN
5 mg/day and 117 LEN 10 mg/day). Other treatments (n = 108)
included thalidomide (n = 19), all-trans-retinoic acid (n = 10),
valproic acid (n = 2), arsenic (n = 2), hydroxyurea (n = 7), activin
soluble receptors (ligand traps; n = 2), low-dose cytarabine (n = 6),
and ATG with or without ciclosporine (n = 15). Median time from
ESA failure to initiation of HMAs and LEN was 15 and 11 months,
respectively (P = .1). Median number of treatment cycles of HMAs
and LEN received was seven and four, respectively. Response rate to
HMAs and LEN (including HI-E, complete response, and partial
response) was 25% and 38%, respectively.
After second-line treatment, 253 patients received third-line
treatment (HMAs, n = 60; LEN, n = 139; and MISC, n = 54), with
a median interval between second- and third-line treatments of
3.6 months; 61 patients received fourth-line treatment (HMAs,
n = 26; LEN, n = 8; HMAs plus LEN, n = 1; and other treatments,
n = 26), and 14 patients received fifth-line treatment (HMAs, n = 8;
LEN, n = 1; and other treatments, n = 5; Appendix Table A2).
Median duration of third- and fourth-line treatments was 4.7 and
3.6 months, respectively. Twenty-eight patients received an HMA
followed by LEN, and 56 patients received LEN followed by an
HMA. Only two patients underwent allogeneic transplantation as
third- and fifth-line treatments, respectively.
Focusing on second-line treatment to study the impact of
treatment strategies after ESA failure, the baseline characteristics of
patients in the MISC group versus those receiving HMAs versus
LEN differed significantly in terms of age and WHO classification.
Median age was higher in the MISC group (75 v 72 and 72 years;
P, .01); there weremoremales in the HMA group (72% v 61% for
MISC and 62% for LEN; P = .02), moreMDSwith ring sideroblasts
in patients treated with LEN or HMAs (65% and 48% v 33%,
respectively; P , .001), and more patients with an intermediate
IPSS-R score at loss of ESA response among those treated with LEN
(34%) or HMAs (33%) versus MISC (16%; P , .001; Table 1).
IPSS-R score at second-line treatment initiation was available in
317 patients and was intermediate in 48% and 22% of patients
receiving LEN and HMAs, respectively, compared with 23% for the
MISC group.
After ESA failure, significantly more progressions to higher-
risk IPSS-R groups were seen in the HMA group compared with
the other treatments (8% for HMA v 4% for LEN and 2% for
MISC; P , .001), despite the exclusion of patients having expe-
rienced progression clearly to an intermediate-II or high IPSS score
or IPSS-R high or very high score at ESA failure (Table 1). More
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Fig 1. Kaplan-Meier estimates of overall survival from erythropoiesis-stimulating
agent (ESA) failure according to primary or secondary failure after ESA treatment
(P = .12).
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characterized the HMA and LEN groups compared with the MISC
group (P , .001).
Impact of Treatment Strategies After ESA Failure
Five-year AML transformation cumulative incidence was
20.3%, 20.3%, and 11.3% for those receiving HMAs, LEN, and
MISC, respectively (P = .05; Fig 2). In multivariable analysis, after
adjusting for second-line treatment received after ESA failure as
a time-dependent variable, age older than 75 years (HR, 0.56;
95% CI, 0.35 to 0.88; P = .01) and secondary failure (with duration
of response to ESA. 6 months); HR, 0.425; 95% CI, 0.24 to 0.75;
P = .003) were associated with lower AML progression rates
(Table 2). Increased AML incidence was associated with primary
versus secondary failure of ESAs rather than with IPSS-R risk at
ESA failure. The HMA group had a higher risk of AML progression
(HR, 1.78; P = .02), possibly related to the higher proportion of
patients with an intermediate IPSS-R score at ESA failure (HR,
1.62; P = .19 for IPSS-R intermediate score; Table 2).
Five-year OS after ESA failure was 36.5%, 41.7%, and 51%
after HMAs, LEN, and MISC, respectively (P = .21; Fig 3). In
a model integrating type of treatment, age, sex, and IPSS-R score at
ESA failure (Table 3), age older than 75 years (HR, 1.73; 95% CI,
1.41 to 2.13; P , .001) and intermediate IPSS-R score (HR, 2.86;
95% CI, 1.91 to 4.30; P , .001) remained significantly associated
with worse OS. There was no significant influence of treatment as
a time-dependent variable on OS (HR, 1.26; 95% CI, 0.97 to 1.64;
P = .08 for HMA; HR, 1.13; 95% CI, 0.80 to 1.59; P = .51 for LEN;
Table 3).
In the heterogeneous MISC group, we conducted a sensi-
tivity analysis by repeating our multivariable analyses after ex-
clusion of patients who received other active treatments, with
results (comparing patients who received HMAs v LEN v RBCs)
similar to those obtained with the whole MISC group (Appendix
Table A3, online only). Although there was no influence of
treatment as a time-dependent variable on OS (HR, 1.22; 95%
CI, 0.93 to 1.58; P = .15 for HMAs; HR, 1.09; 95% CI, 0.77 to
1.55; P = .62 for LEN), HMA use did affect risk of AML
transformation (HR, 1.85; 95% CI, 1.11 to 3.10; P = .02; Table 2).
In the 15 patients who received ATG, 5-year OS was 50.0% and
did not significantly differ from that of other patients in the
MISC group.
Causes of death were predominantly infection (26%) and
AML transformation (23%) in the HMA group and infection
(22%) and AML transformation (15%) in the LEN group. There
were no excess deaths resulting from secondary cancers in the LEN
group (2%). Deaths in the MISC group resulted from infection
(20%), AML transformation (12%), and unknown causes (49%),
probably related to patient comorbidities.











Median 72 72 75
Q1-Q3 64-76 65-78 68-81
Female sex 57 (38) 55 (28) 314 (39) .02
WHO classification at ESA failure , .001
RA 18 (15) 32 (29) 88 (38)*
MDS with ringed sideroblasts 75 (65) 53 (48) 63 (33)*
RAEB-1 18 (16) 18 (16) 17 (12)*
MDS-U 4 (3) 4 (3) 8 (5)*
IPSS-R at ESA failure , .001
Very low 4 (3) 7 (4) 119 (17)*
Low 92(63) 109 (63) 471(67)*
Intermediate 49 (34) 57 (33) 111 (16)*
IPSS-R progression at ESA failure 6 (4) 16 (8) 16 (2) , .001
Abbreviations: ESA, erythropoiesis-stimulating agent; HMA, hypomethylating agent; IPSS-R, revised International Prognostic Scoring System; LEN, lenalidomide;MDS,
myelodysplastic syndromes; MDS-U, myelodysplastic syndromes unclassified; MISC, other treatments or RBC transfusion only; Q, quartile; RA, refractory anemia;
RAEB, refractory anemia with excess blasts.
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Fig 2. Simon-Makuch model (with treatment as a time-dependent variable) of
cumulative acute myeloid leukemia (AML) incidence in patients receiving lenali-
domide (LEN) or hypomethylating agents (HMAs) versus other treatments or RBC
transfusion only (MISC) as second-line treatment (from erythropoiesis-stimulating
agent failure; P = .05).
1594 © 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Park et al
DISCUSSION
This study, combining patients from eight data sets (six large
retrospective registries and two prospective trials) is, to our
knowledge, the largest to present the outcome of patients with
lower-risk MDS who did not respond to ESAs or experienced
relapse after an initial response to ESAs. We found that patients
experiencing primary ESA failure had a higher risk of pro-
gression to AML than those experiencing secondary failure,
although this did not translate into a significant OS differ-
ence between the two groups. Second-line treatments (HMAs
and LEN) had no significant influence on OS compared with
MISC.
In our study, the response rate to ESAs was 61.5%, and
median response duration was 17 months, similar to other
published results in lower-risk MDS, in which most patients have
serum EPO levels, 500 U/l (in our study, median serum EPO level
was 203 U/l) and no or limited RBC transfusion requirements. In
addition to well-known factors predictive of response to ESAs,
including lower serum EPO level, IPSS-R score, and ferritin level,
we found that MDS with ring sideroblasts were more frequent
among primary refractory patients, a result described by other
groups.16,17
Median OS from ESA failure was 52 and 60months in patients
experiencing primary failure and relapse, respectively. Early ESA
failure (primary failure or relapse within 6 months of response)
was associated with a higher risk of AML progression, which did
not translate into worse OS.
Results of our multivariable model showed that simple clinical
and biologic characteristics, including age and IPSS-R score, could
predict OS. This further stresses the prognostic value of IPSS-R
both for responsiveness to ESA treatment5 and for outcome after
ESA failure.
The second main conclusion of our work is that the in-
troduction of an active treatment like HMAs or LEN after ESA
failure had no obvious influence on OS. Main causes of death
were AML transformation and infection, as previously described,
which differed in the MISC group.18 The HMA group had
a higher incidence of AML progression, possibly related to the
higher proportion of patients with an intermediate IPSS-R score
at the time of ESA failure, despite adjustment for this variable in
multivariable analyses. One limitation of this study is the con-
founding influence of the indication for subsequent therapies in
patients who may have fewer comorbidities and are thus pre-
dicted to live longer than those receiving RBC transfusions only.
Despite this potential bias, no survival advantage was observed
with HMA or LEN use in this selected population of lower-risk
patients at ESA initiation.
Of note, our outcome analysis was performed focusing on
second-line treatment, whereas some patients received sev-
eral successive treatments after ESA failure. In contrast, after
Table 2. Prognostic Factors for Cumulative AML Incidence After ESA Failure (multivariable analysis)
Factor HR 95% CI P
Second-line treatment after ESAs*
HMAs 1.78 1.08 to 2.93 .02
LEN 1.46 0.77 to 2.78 .24
Age . 75 years 0.57 0.35 to 0.91 .02
Female sex† 1.01 0.65 to 1.57 .95
IPSS-R progression at ESA failure‡ 1.33 0.61 to 2.91 .47
IPSS-R score at loss of response to ESAs‡
Intermediate 1.62 0.78 to 3.37 .19
Low 0.71 0.36 to 1.44 .34
Secondary ESA failure, duration of response to ESAs§
# 6 months 0.67 0.23 to 1.93 .46
. 6 months 0.41 0.23 to 0.75 .002
NOTE. IPSS-R progression at ESA failure versus initiation of ESAs indicates patients whose IPSS-R score progressed between ESA failure and ESA initiation.
Abbreviations: AML, acute myeloid leukemia; ESA, erythropoiesis-stimulating agent; HMA, hypomethylating agent; HR, hazard ratio; IPSS-R, revised International
Prognostic Scoring System; LEN, lenalidomide.
*Other treatments or RBC transfusion only as reference group.
†Male sex as reference group.
‡Very low risk as reference group.
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Fig 3. Simon-Makuch model (with treatment as a time-dependent variable) of
overall survival in patients receiving lenalidomide (LEN) or hypomethylating agents
(HMAs) at second-line treatment versus other treatments or RBC transfusion only
(MISC; from erythropoiesis-stimulating agent failure; P = 0.21).
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second-line treatment, the influence of other lines of treatment on
OS could not be assessed in multivariable analyses, because of the
limited number of patients in each subgroup.
In conclusion, early failure of ESAs was associated with
a higher incidence of AML transformation, which did not translate
into worse OS, within the limited follow-up in this study. IPSS-R
intermediate score was associated with worse outcome, and pri-
mary resistance to ESAs was associated with a higher incidence of
AML transformation. Second-line treatment with LEN or HMAs
after ESA failure did not significantly influence OS. This study may
be important in designing future clinical trials involving patients
with lower-riskMDS for whom ESA treatment fails, in whom novel
treatments are required. Parameters predicting worse outcome,
including IPSS-R subtype and duration of response to ESAs, could
indicate a more intensive therapeutic approach, including allo-
geneic stem-cell transplantation.
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Stéphane Cheze




No relationship to disclose
Norbert Vey
Honoraria: Celgene, Novartis, Amgen, Bristol-Myers Squibb
Consulting or Advisory Role: Novartis, Roche
Travel, Accommodations, Expenses: Novartis, Amgen
Daniela Gioia
No relationship to disclose
© 2017 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Park et al
Dario Ferrero
Travel, Accommodations, Expenses: Novartis, Celgene, Bristol-Myers
Squibb
Gianluca Gaidano
No relationship to disclose
Giovanni Cametti
No relationship to disclose
Fabrizio Pane
No relationship to disclose
Alessandro Sanna
No relationship to disclose
Ulrich Germing
Honoraria: Janssen-Cilag, Amgen, Celgene, Novartis
Guillermo F. Sanz
Honoraria: Celgene
Consulting or Advisory Role: Amgen, Janssen Pharmaceuticals
François Dreyfus
No relationship to disclose
Pierre Fenaux
No relationship to disclose
jco.org © 2017 by American Society of Clinical Oncology
Outcome in Non-del5q Lower-Risk MDS After ESA Failure
Appendix








(n = 653) Three Groups Relapse v Primary Resistance
Age, years , .001 , .001
Median 76 74 72
Q1-Q3 71-83 68-81 66-80
Female sex 275 (50) 200 (40) 226 (35) , .001 .04
WHO classification at ESA initiation , .001 .002
RA without excess of blasts 343 (38) 239 (27) 309 (34)
MDS with ringed sideroblasts 130 (25) 191 (36) 207 (39)
RAEB-1 47 (31) 34 (22) 70 (46)
RCUD or MDS-U 31 (24) 30 (23) 67 (52)
HgB at ESA initiation, g/dl , .001 .004
Median 9.4 9.2 9.0
Q1-Q3 8.8-10.0 8.5-9.9 8.2-9.7
IPSS-R score at ESA initiation , .001 .002
Very low 126 (45) 77 (27) 80 (28)
Low 305 (32) 292(31) 352 (37)
Intermediate 46 (20) 61 (26) 126 (54)
High 4 (100) 0 0
Not evaluable* 70 (30) 64 (28) 95 (41)
Serum ferritin, mg/L , .001 .06
Median 426 506 578
Q1-Q3 126-552 188-620 220-740
Serum EPO level, mU/mL , .001 , .001
Median 60 183 245
Q1-Q3 21-75 38-323 49-260
IPSS-R progression at ESA failure v initiation NA 26 (16) 22 (13) .44 .44
Abbreviations: EPO, erythropoietin; ESA, erythropoiesis stimulating agent; HgB, hemoglobin; IPSS-R, revised International Prognostic Scoring System; MDS, mye-
lodysplastic syndromes; MDS-U, myelodysplastic syndromes unclassified; NA, not applicable; Q, quartile; RA, refractory anemia; RAEB, refractory anemia with excess
blasts; RCUD, refractory cytopenia with unilineage dysplasia.
*Marrow blasts , 5%.
Table A2. Treatments (other than RBC transfusion) Administered After ESA
Failure
Treatment
Treatment Line (No. of patients)
Second Third Fourth
HMAs 194 60 26
LEN 148 139 9
Other* 108 54 26
Abbreviations: ESA, erythropoiesis stimulating agent; HMA, hypomethylating
agent; LEN, lenalidomide.
*Valproic acid, ACE-536 or -011, thalidomide, antithymocyte globulin 6 ciclo-
sporine, low-dose cytarabine, hydroxyurea, or all-trans-retinoic acid.
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Excluded
  MDS with del(5q) and
    CMML
  Progression to higher-
    risk IPSS score at loss
    of response to ESAs
Patients with lower-risk
(by  IPSS) MDS receiving
ESA treatment with data
on outcome (N = 1,698)
French, Spanish, Italian,
Düsseldorf, Munich, Greek, and
US registries 
GFM trial: LEN plus EPO
GFM trial: AZA plus EPO
Persisting response
(n = 551; 32.5%)
Relapse
(n = 494; 29%)
Primary resistance
(n = 653; 38.5%)
Response rate to ESAs, 61.5%











Fig A1. CONSORT diagram. AZA, azacitidine; CMML, chronic myelomonocytic leukemia; EPO, erythropoietin; ESA, erythropoiesis-stimulating agent; GFM, Groupe
Francophone des Myelodysplasies; HMA, hypomethylating agent; IPSS, International Prognostic Scoring System; LEN, lenalidomide; MDS, myelodysplastic syndromes;
MISC, other treatments or RBC transfusion only.
Table A3. Multivariable Analysis of Sensitivity for OS*
Variable HR 95% CI P†
Second-line treatment‡
HMAs 1.217 0.934 to 1.586 .146
LEN 1.093 0.772 to 1.548 .615
Age . 75 years 1.701 1.380 to 2.096 , .001
gender (ref: male)
Female sex§ 0.848 0.682 to 1.055 .140
IPSS-R progression at ESA failure v initiation 0.753 0.449 to 1.262 .281
IPSS-R score at ESA failure
Intermediate 2.908 1.925 to 4.391 , .001
Low 1.353 0.931 to 1.967 .113
Duration of response . 6 months 0.840 0.669 to 1.054 .132
Abbreviations: ATG, antithymocyte globulin; ESA, erythropoiesis stimulating agent; HMA, hypomethylating agent; HR, hazard ratio; IPSS-R, revised International
Prognostic Scoring System; LEN, lenalidomide; MISC, other treatments or RBC transfusion only; OS, overall survival.
*Excluding patients who received active treatment (defined as ATG [n = 15]) in the MISC group.
†From z score.
‡MISC without ATG as reference group.
§Male sex as reference group.
jco.org © 2017 by American Society of Clinical Oncology





592 459 342 253 160 101Primary resistance
416 320 239 174 125 86Loss of response
No. at risk:























Fig A2. Cumulative acute myeloid leukemia (AML) incidence according to pri-
mary (primary resistance) or secondary failure (loss of response; P , .001).
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